Your session is about to expire
← Back to Search
Urokinase-type Plasminogen Activator
LTI-01 for Pleural Effusion
Phase 2
Waitlist Available
Research Sponsored by Lung Therapeutics, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Male or female ≥ 18 years of age who provide written informed consent
Clinical presentation compatible with complicated parapneumonic pleural effusion (CPE), empyema or other type of pleural infection
Timeline
Screening 3 weeks
Treatment Varies
Follow Up post treatment (day 4 or at time of treatment failure)
Awards & highlights
Study Summary
This trial is testing a new drug to see if it can treat patients with an infection in their lungs.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ post treatment (day 4 or at time of treatment failure)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~post treatment (day 4 or at time of treatment failure)
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence of referral to surgery
Secondary outcome measures
Relative change in pleural opacity
Trial Design
4Treatment groups
Experimental Treatment
Placebo Group
Group I: 800,000 U LTI-01Experimental Treatment1 Intervention
800,000 U LTI-01 qd x 3 days administered intrapleurally
Group II: 400,000 U LTI-01Experimental Treatment1 Intervention
400,000 U LTI-01 once a day (qd) x 3 days administered intrapleurally
Group III: 1,200,000 U LTI-01Experimental Treatment1 Intervention
1,200,000 U LTI-01 qd x 3 days administered intrapleurally
Group IV: PlaceboPlacebo Group1 Intervention
placebo (normal saline) 6ml qd x 3 days administered intrapleurally
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Saruplase
Not yet FDA approved
Find a Location
Who is running the clinical trial?
Lung Therapeutics, IncLead Sponsor
2 Previous Clinical Trials
95 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger